Scarica l'app Stockscreener
1.39
9.45%
0.12
Dopo l'orario di chiusura:
1.43
0.04
+2.88%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.27
Aprire:
$1.28
Volume 24 ore:
7.29M
Relative Volume:
3.79
Capitalizzazione di mercato:
$254.87M
Reddito:
$137.74M
Utile/perdita netta:
$-27.97M
Rapporto P/E:
-8.6875
EPS:
-0.16
Flusso di cassa netto:
$-9.61M
1 W Prestazione:
+10.32%
1M Prestazione:
+4.51%
6M Prestazione:
-37.67%
1 anno Prestazione:
-13.13%
Intervallo 1D:
$1.28
$1.575
Intervallo di 1 settimana:
$1.18
$1.575
Portata 52W:
$0.9999
$2.68
Heron Therapeutics Inc Stock (HRTX) Company Profile
Nome
Heron Therapeutics Inc
Settore
Industria
Telefono
(858) 251-4400
Indirizzo
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Confronta HRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.39 | 232.87M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2024-04-23 | Iniziato | CapitalOne | Overweight |
| 2024-03-13 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Buy |
| 2020-02-20 | Reiterato | Needham | Buy |
| 2019-01-16 | Reiterato | Needham | Buy |
| 2018-04-05 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Reiterato | Mizuho | Buy |
| 2018-03-01 | Reiterato | Needham | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Outperform |
| 2017-09-27 | Iniziato | Northland Capital | Outperform |
| 2017-02-27 | Iniziato | Needham | Buy |
| 2016-10-26 | Iniziato | Aegis Capital | Buy |
| 2016-09-06 | Ripresa | Lake Street | Buy |
| 2016-05-03 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-10 | Iniziato | Lake Street | Buy |
| 2015-09-23 | Reiterato | Leerink Partners | Outperform |
| 2015-09-02 | Iniziato | BofA/Merrill | Buy |
| 2015-08-03 | Reiterato | Brean Capital | Buy |
| 2015-06-30 | Reiterato | JMP Securities | Mkt Outperform |
| 2015-06-19 | Reiterato | Leerink Partners | Outperform |
| 2014-08-07 | Iniziato | Noble Financial | Buy |
Mostra tutto
Heron Therapeutics Inc Borsa (HRTX) Ultime notizie
Heron Therapeutics’ Revenue Soars Beyond Expectations in Q4 2025 - StocksToTrade
Heron Therapeutics Revenue Exceeds Estimates with Strong Acute Care Performance - StocksToTrade
Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M - Yahoo Finance
How supply chain issues affect Heron Therapeutics Inc. stockMarket Sentiment Review & Real-Time Stock Movement Alerts - ulpravda.ru
How Heron Therapeutics Inc. stock reacts to global recession fears2025 Price Momentum & Daily Profit Focused Stock Screening - ulpravda.ru
Can Heron Therapeutics Inc. stock surprise with earnings upsideCEO Change & Real-Time Buy Signal Alerts - ulpravda.ru
Heron Therapeutics Expands Strategic Vision Amid Market Fluctuations - StocksToTrade
Heron Therapeutics Reports Strong Preliminary Q4 2025 Revenue - TipRanks
HRTX: HC Wainwright & Co. Reiterates Buy Rating with $6 Price Ta - GuruFocus
Heron Therapeutics' (HRTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Heron Therapeutics stock soars after strong Q4 revenue growth By Investing.com - Investing.com Canada
Heron rises as revenue figures exceed estimates (HRTX:NASDAQ) - Seeking Alpha
Heron Therapeutics announces preliminary, unaudited Q4 results - MarketScreener
Heron Therapeutics Reports Preliminary Fourth Quarter and Full-Year 2025 Financial Results - Quiver Quantitative
Heron Therapeutics Announces Preliminary, Unaudited Q4 and - GlobeNewswire
Will Heron Therapeutics Inc. stock gain from strong economy2025 Key Lessons & Long-Term Growth Stock Strategies - ulpravda.ru
What technical signals suggest for Heron Therapeutics Inc. stock2025 Retail Activity & Daily Profit Maximizing Tips - ulpravda.ru
Does Heron Therapeutics Inc. stock trade at a discount to peers2025 Bull vs Bear & High Yield Stock Recommendations - ulpravda.ru
How analysts rate Heron Therapeutics Inc. stock todayWeekly Gains Summary & Verified Momentum Stock Alerts - ulpravda.ru
Will Heron Therapeutics Inc. stock maintain dividend yield2025 Volatility Report & Long Hold Capital Preservation Tips - ulpravda.ru
Can Heron Therapeutics Inc. stock sustain market leadershipIndustrial Stocks Review & High Profit Growth Stocks - ulpravda.ru
Will Heron Therapeutics Inc. stock outperform tech sector in 20252026 world cup usa national team group stage star players high defensive line tactical prediction insights - ulpravda.ru
Is Heron Therapeutics Inc AXD2 a good long term investmentConsumer Goods Stocks & Small Capital Gains - earlytimes.in
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Exit Recap: Does Heron Therapeutics Inc stock trade at a discount to peers2025 Market WrapUp & Verified Momentum Watchlists - moha.gov.vn
What analysts say about Heron Therapeutics Inc AXD2 stockContrarian Investment Ideas & High Return Investment Growth - earlytimes.in
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Investor Mood: Will Heron Therapeutics Inc stock outperform tech sector in 2025Bear Alert & Long Hold Capital Preservation Tips - moha.gov.vn
Is Heron Therapeutics Inc. stock attractive for income investorsJuly 2025 Highlights & Capital Protection Trading Alerts - Улправда
Is Heron Therapeutics Inc. stock cheap at current valuationJuly 2025 Drop Watch & Safe Investment Capital Preservation Plans - DonanımHaber
Can Heron Therapeutics Inc. stock sustain revenue growthJuly 2025 Review & Growth Focused Stock Reports - Улправда
Is Heron Therapeutics Inc. stock gaining market shareInflation Watch & Community Consensus Trade Alerts - Улправда
Heron Therapeutics Earnings Notes - Trefis
Congress Park Capital LLC Acquires 621,908 Shares of Heron Therapeutics, Inc. $HRTX - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Catapults 27% Though Its Price And Business Still Lag The Industry - simplywall.st
Heron Therapeutics, Inc. (NASDAQ:HRTX) is favoured by institutional owners who hold 57% of the company - Yahoo Finance
Heron Therapeutics Appoints Thomas Cusack to Board - MSN
Heron Therapeutics Reports Strong Q3 2025 Revenue Growth - MSN
Heron Therapeutics Inc (HRTX) can make a big difference with a little luck - setenews.com
Heron Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Heron Therapeutics enters board agreement and completes refinancing transactions By Investing.com - Investing.com Nigeria
Activity Recap: Will Heron Therapeutics Inc stock deliver long term returnsDividend Hike & Weekly Market Pulse Updates - BỘ NỘI VỤ
San Diego Biotech Firm Heron Therapeutics Shifts Operations to North Carolina - MSN
What analysts say about Heron Therapeutics Inc stockGrowth Stock Opportunities & 5 Stocks Every Investor Should Own - earlytimes.in
Market Sentiment Around Loss-Making Heron Therapeutics, Inc. (NASDAQ:HRTX) - simplywall.st
Can Heron Therapeutics Inc. stock sustain institutional interestMarket Trend Report & High Return Trade Guides - Newser
Can Heron Therapeutics Inc. (AXD2) stock expand revenue streamsWeekly Profit Analysis & Fast Entry and Exit Trade Plans - Newser
How cyclical is Heron Therapeutics Inc. (AXD2) stock compared to rivalsJuly 2025 Setups & Fast Entry High Yield Tips - Newser
Heron Therapeutics announces inclusion of Aponvie (aprepitant) - marketscreener.com
Heron Therapeutics Announces Inclusion of APONVIE® - GlobeNewswire
Heron Therapeutics Inc Azioni (HRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):